Bromelain topical - MediWound

Drug Profile

Bromelain topical - MediWound

Alternative Names: Debrase; Debrase Gel Dressing; KMW-1; NexoBrid; NexoBridN

Latest Information Update: 27 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator MediWound
  • Developer MediWound; Teva Pharmaceutical Industries; Tuteur
  • Class Anti-inflammatories; Cysteine endopeptidases; Skin disorder therapies
  • Mechanism of Action Peptide hydrolase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Burns
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Burns

Most Recent Events

  • 16 Dec 2017 Kaken Pharmaceutical plans a phase I trial for Burns (In volunteers, In adults, In the elderly) in Japan (UMIN000030423)
  • 16 Oct 2017 Bromelain topical licensed to Holy Stone Healthcare in Taiwan
  • 03 Aug 2017 MediWound submits protocol for the phase III Children Innovative Debridement Study with the US FDA in USA for Burns (In adolescents, In children, In infants)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top